INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← Oncology / Health Desk

Carrots and cancer: a prospective association, not a prevention trial

A review separated reported carrot intake from a blood biomarker and found inverse associations for both.

Whole-food ingredients prepared without added oil

Illustrative food image, not a photograph of the study intervention.

What the carrot comparison found

The review examined carrot intake and cancer incidence using prospective observational studies. In 50 prospective studies recording carrot intake, with 52,000 cases, the highest-versus-lowest intake comparison gave a summary relative risk of 0.90. Its 95% confidence interval was 0.87 to 0.94. This is an association between reported intake and subsequent cancer incidence, not a randomized test of eating carrots. The distinction is central to interpreting the finding: the pooled estimate does not establish that assigning someone more carrots would reproduce that relative risk. The authors explicitly call for further investigation of causal mechanisms.

Ojobor CC, O'Brien GM, Siervo M, Ogbonnaya C et al.. Critical reviews in food science and nutrition, 2025. PMID 38104588 · DOI

A separate blood-marker analysis

The authors also analyzed plasma alpha-carotene, which they described as a non-causal biomarker of carrot consumption. Across 30 prospective studies with 9,331 cases, the summary relative risk comparing the highest and lowest concentrations was 0.80, with a 95% confidence interval of 0.72 to 0.89. This is a different exposure from reported carrot intake. It should not be presented as a second estimate for the same dietary comparison, or as evidence that alpha-carotene supplementation prevents cancer. The review distinguishes the biomarker from the food, and its description of the biomarker as non-causal is important to preserve.

Ojobor CC, O'Brien GM, Siervo M, Ogbonnaya C et al.. Critical reviews in food science and nutrition, 2025. PMID 38104588 · DOI

Consistency still includes variation

The investigators searched for studies published before June 2022 and supplemented their search by checking included studies and reviews. Their highest-versus-lowest comparisons used random-effects meta-analysis. For both carrot intake and plasma alpha-carotene, the abstract describes between-study heterogeneity as moderate. That means the summary estimates belong with an acknowledgment of variation, rather than a claim that all studies produced the same result. The reported interaction with cancer type was not significant. That does not establish an identical benefit for every cancer site; it describes the interaction analysis in this review of prospective observational evidence.

Ojobor CC, O'Brien GM, Siervo M, Ogbonnaya C et al.. Critical reviews in food science and nutrition, 2025. PMID 38104588 · DOI

Dose-response is not a prescription

The abstract reports significant dose-response findings for both exposure types, with P values below 0.01. It does not provide a specific carrot portion corresponding to a defined reduction in absolute cancer risk. A dose-response association therefore should not become a serving prescription in a summary of this paper. The authors also note that beta-carotene has shown no benefit in controlled cancer trials, despite carrots containing several compounds of interest. That contrast reinforces the need to keep whole-food associations, blood biomarkers, and supplement trials separate. The positive finding here is an observational association with cancer incidence, not evidence of cancer treatment.

Ojobor CC, O'Brien GM, Siervo M, Ogbonnaya C et al.. Critical reviews in food science and nutrition, 2025. PMID 38104588 · DOI